Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.

Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F.

Cancers (Basel). 2012 Jun 5;4(2):549-65. doi: 10.3390/cancers4020549.

PMID:
24213324
[PubMed]
Free PMC Article
2.

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

Lencioni R, Chen XP, Dagher L, Venook AP.

Oncologist. 2010;15 Suppl 4:42-52. doi: 10.1634/theoncologist.2010-S4-42. Review.

PMID:
21115580
[PubMed - indexed for MEDLINE]
Free Article
3.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
[PubMed - indexed for MEDLINE]
4.

Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.

Choi JY.

Oncology. 2011;81 Suppl 1:141-7. doi: 10.1159/000333277. Epub 2011 Dec 22.

PMID:
22212948
[PubMed - indexed for MEDLINE]
5.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
[PubMed - indexed for MEDLINE]
6.

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.

Eur J Gastroenterol Hepatol. 2010 Apr;22(4):391-8. doi: 10.1097/MEG.0b013e328333df23.

PMID:
19940784
[PubMed - indexed for MEDLINE]
7.

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Kudo M.

Oncology. 2008;75 Suppl 1:1-12. doi: 10.1159/000181865. Epub 2008 Dec 17. Review.

PMID:
19092266
[PubMed - indexed for MEDLINE]
8.

Sorafenib for the treatment of advanced hepatocellular carcinoma.

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D.

Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03. Review.

PMID:
20507799
[PubMed - indexed for MEDLINE]
Free Article
9.

Sorafenib for the treatment of hepatocellular carcinoma across geographic regions.

Hsu C, Shen YC, Cheng AL.

Expert Rev Clin Pharmacol. 2009 Mar;2(2):129-36. doi: 10.1586/17512433.2.2.129.

PMID:
24410643
[PubMed]
10.

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.

Oncologist. 2009 Jan;14(1):70-6. doi: 10.1634/theoncologist.2008-0191. Epub 2009 Jan 14.

PMID:
19144684
[PubMed - indexed for MEDLINE]
Free Article
11.

Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.

Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:37-51. doi: 10.2165/1163024-S0-000000000-00000.

PMID:
22873626
[PubMed - indexed for MEDLINE]
12.

Sorafenib: from literature to clinical practice.

Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype C.

Ann Oncol. 2013 Apr;24 Suppl 2:ii30-7. doi: 10.1093/annonc/mdt055. Review.

PMID:
23715941
[PubMed - indexed for MEDLINE]
Free Article
13.

Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma.

Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T.

Exp Ther Med. 2012 Sep;4(3):381-386. Epub 2012 Jun 15.

PMID:
23181103
[PubMed]
Free PMC Article
15.

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

Rimassa L, Santoro A.

Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41.

PMID:
19496710
[PubMed - indexed for MEDLINE]
16.

Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.

Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.

Anticancer Drugs. 2010 Mar;21(3):326-32. doi: 10.1097/CAD.0b013e3283350e26.

PMID:
20016366
[PubMed - indexed for MEDLINE]
17.

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.

Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1106-10. doi: 10.1097/MEG.0b013e3283386053.

PMID:
20300004
[PubMed - indexed for MEDLINE]
18.

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Kudo M, Ueshima K.

Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8. Review.

PMID:
20616599
[PubMed - indexed for MEDLINE]
19.

Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.

Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M.

Oncology. 2013;84(2):108-14. doi: 10.1159/000342650. Epub 2012 Nov 9.

PMID:
23147476
[PubMed - indexed for MEDLINE]
20.

Updated treatment approach to hepatocellular carcinoma.

Llovet JM.

J Gastroenterol. 2005 Mar;40(3):225-35. Review.

PMID:
15830281
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk